Background: Inhaled bronchodilators are first line drugs in the treatment of chronic obstructive pulmonary disease (COPD). Tiotropium bromide is a recently introduced longacting anticholinergic agent able to reduce dyspnoea and COPD exacerbations and to improve pulmonary function and quality of life. We designed a study to compare the shortterm efficacy of tiotropium bromide with that of oxitropium bromide in improving pulmonary function in patients with COPD. Methods: Eighty patients were randomized either to continue oxitropium 800 mcg/day or to receive tiotropium 18 mcg/day. Seventy-six (39 in the tiotropium and 37 in the oxitropium group) completed the study. Plethysmography was performed at baseline and after 72 h in all patients. The changes in functional parameters in the two groups were compared by the Mann-Whitney U-test. Results: There were no differences between the two groups regarding age (72.5 vs. 74.2 years), male/female ratio (25/14 vs. 23/14) and pulmonary function at baseline. The changes in spirometric parameters were significantly greater in tiotropium-than in oxitropium-treated patients: mean forced expiratory volume in 1 s (FEV 1 ) increased significantly by 15% vs. 3% (P ¼ 0:017), mean FVC by 10.5% vs. 2.2% (P ¼ 0:044), and FEF 25, 50, and 75 by 34% vs. 14% (Po0.05), 33% vs. 7% (Po0.05), and 50% vs. 6% (Po0.0001), respectively; mean FRC and RV decreased nonsignificantly by 7.5% and 10% with tiotropium vs. 4.3% and 6.5% with oxitropium, respectively. Conclusion: The replacement of oxitropium with tiotropium significantly increases pulmonary function in patients with COPD. The improvement involves also small airways that have not been investigated thus far.
Introduction
Inhaled bronchodilators, namely b2-agonists and anticholinergics, are the mainstay of treatment for chronic obstructive pulmonary disease (COPD). [1] [2] [3] They are able to improve symptoms and exercise capacity, 4 and to decrease the frequency of COPD exacerbations. 5, 6 Tiotropium bromide is a second-generation anticholinergic agent that is structurally related to ipratropium bromide. Its main distinguishing characteristic is slow dissociation from Hm1 and Hm3 muscarinic receptors, 7 which results in sufficiently prolonged pharmacological activity 8 to allow once daily administration. After the first dose, mean time to onset of its bronchodilating effect is 30 min and mean time to peak effect is about 3 h. Subsequent doses increase efficacy even further until maximum bronchodilating activity is achieved after 1 week. 9 A number of clinical studies have demonstrated the efficacy of tiotropium in reducing dyspnoea and COPD exacerbations and in improving quality of life. [10] [11] [12] Moreover, significant effects on pulmonary function have been reported, namely increase in forced expiratory volume in 1 s (FEV 1 ) and forced vital capacity (FVC), 13 and decrease in functional residual capacity (FRC), which indicates that the drug reduces lung hyperinflation. 14 The objective of this study was to assess short-term changes in pulmonary function, including small airways variables, in patients with COPD on treatment with another anticholinergic agent, oxitropium bromide, during either continuation of treatment with oxitropium bromide or replacement treatment with tiotropium bromide.
Materials and methods

Patients
Eighty patients referred to the Unit of Pulmonary Rehabilitation of the ICP Hospital in Milan were included in the study. To be included, patients had to be in stable conditions, with no exacerbations for at least 2 months, in GOLD stage 2-4 according to FEV 1 values, 1 and on treatment with only oxitropium bromide as bronchodilator. Treatment with other bronchodilators or inhaled corticosteroids was an exclusion criterion. The patients were randomized either to continuation of treatment with oxitropium (800 mcg daily) or to replacement of oxitropium with tiotropium (18 mcg daily). In patients maintained on treatment with oxitropium, the inhalation technique was optimized by using spacer devices, if they had not been already introduced. The need to inhale the drug every 6 h was stressed. Patients initiating treatment with tiotropium were instructed to use the dry powder inhaler device.
Methods
Pulmonary function
The FEV 1 , the FVC, the expiratory flows at low volumes (FEF 25, 50, and 75), the FRC, and the residual volume (RV) were measured by an automated pulmonary function testing center (6200 Autobox DL, Sensor Medics, Yorba Linda, CA, USA) in accordance with recognized standards. 15 Variables were measured at inclusion and after 72 h: this interval was chosen to avoid confounding by pulmonary rehabilitation procedures. 16 The last dose before repeat measurement was given 3 h before for oxitropium and 1 h before for tiotropium.
Statistical analysis
The differences in the absolute changes of respiratory parameters between post-and pre-intervention in tiotropium-and oxitropium-treated patients were analysed by the Mann-Whitney U-test, setting a P value lower than 0.05 as significant.
Results
Of the 80 patients included, four did not perform the second plethysmography, three (two in the oxitropium and one in the tiotropium group) because they withdrew the informed consent and one (in the oxitropium group) because family problems made compliance with the rehabilitation program difficult. Thus, 76 patients (39 in the tiotropium and 37 in the oxitropium group) were evaluated for the study. Thirteen patients of the oxitropium group did not use any spacer device and were instructed to use it. The baseline characteristics of the two treatment groups are shown in Table 1 : the two groups were well matched.
The changes in each parameter vs. baseline are reported in Table 2 . The increases in mean FEV 1 , FVC, and FEF 25, 50, and 75 were significantly higher in patients treated with tiotropium than in those treated with oxitropium, whereas the decrease in mean FRC and RV was larger in tiotropium treated patients but did not reach statistical significance. This is depicted in Fig. 1 .
Discussion
A considerable body of evidence collected following the introduction of tiotropium bromide into clinical practice makes it a first-line drug for the treatment of COPD. [9] [10] [11] [12] [13] [14] A recent meta-analysis of nine randomized controlled studies has clearly shown that the drug ameliorates symptoms and related quality of life, reduces the incidence of disease exacerbations and improves pulmonary function, as well as increasing exercise capacity. 17 The improvement in spirometric parameters achieved with tiotropium was apparent not only as compared to placebo-treated patients, 13, 14 but also in subjects treated with other bronchodilators. For example, the early increase in mean FEV 1 in patients treated with tiotropium was significantly higher compared to those treated with the long-acting b2-agonist salmeterol 12 and an improvement in FEV 1 value was observed even in patients regularly treated with the other b2-agonist formoterol. 18 The superiority in respect of the first-generation anticholinergic ipratropium is made unmistakable by the meta-analysis, 17 while to our knowledge no comparison with oxitropium is available. In respect to ipratropium, oxitropium has a longer pharmacological action which enables twice a-day dosing and is as effective as ipratropium in terms of the bronchodilating activity. 19 In the present study we compared the short-term effects on pulmonary function parameters of the introduction of tiotropium in patients with COPD, randomizing the subjects either to continue treatment with oxitropium-after optimizing the dosage and the inhaling technique-or to replace it with tiotropium. In oxitropium-treated subjects small increases in FEV 1 , FVC, and FEF 25, 50, and 75 were found, as well as small decreases in FRC and RV, which were likely to be due to the optimization of treatment. The changes were greater in tiotropium-treated patients: mean FEV 1 increased significantly by 15% vs. 3% in oxitropium-treated patients, mean FVC by 10.5% vs. 2.2%, FEF 25 by 34% vs. 14%, FEF 50 by 33% vs. 7%, and FEF 75 by 50% vs. 6%. By contrast, mean FRC decreased nonsignificantly by 7.5% with tiotropium vs. 4.3% with oxitropium, and RV decreased nonsignificantly by 10% vs. 6.5%.
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This degree of improvement is not unexpected, because even higher values were reported in placebo-controlled studies. For example, the first dose of tiotropium increased mean FEV 1 by 16% and mean FVC by 17% in patients with stable COPD. 13 In a long-term study the addition of tiotropium to other standard drug treatments was able to increase mean FEV 1 up to 22% and mean FVC up to 12%. 10 In our study, also the difference in FEF 25, 50, and 75 between tiotropium-and oxitropium-treated patients was significant: tiotropium produced larger increase in these parameters, which are related to small airways calibre, with a P valueo0.05 for FEF 25 and FEF 50, and o0.0001 for FEF 75.
To the best of our knowledge, previous evaluations on the effects of tiotropium on small airways are not available. The improvement we observed, particularly for FEF75, which was the most marked among the spirometric measurements, is likely to be linked to the efficiency of the dry powder inhaler device in delivering the drug into the airways and to the interaction with muscarinic receptors in the smooth muscle of small airways. 20 The importance of this portion of the respiratory tract was recently claimed by a study, in which bioptic evidence disclosed a close correlation between severity of small airway obstruction and clinical severity of COPD. 21 Consequently, future investigation on the efficacy of drug treatment should take into account the changes occurring in small airway calibre. The dilation of small airways is expected to reduce the air trapping and then the hyperinflation parameters. Previous studies reported that treatment with tiotropium achieves a significant decrease in lung hyperinflation, as measured by the inspiratory capacity (IC), an event usually associated with
